Loading…
Uriel Pharmacy, Inc. was cited for significant Current Good Manufacturing Practice (CGMP) violations in the manufacturing of finished pharmaceutical drugs, rendering their products adulterated under federal law. The FDA's February-March 2025 inspection identified failures in the company's methods, facilities, and controls for manufacturing, processing, packing, and holding drugs. Additionally, the company's homeopathic ampule products—including formulations such as Aquilinum Taraxacum, Aurum 6X, and Belladonna ex herba—were found to be unapproved new drugs introduced into interstate commerce in violation of FDA regulations. A critical public health concern was identified: the glass ampule packaging used for these products could be mistaken for injectable drugs, potentially causing serious harm if consumers misunderstood the intended route of administration.